Maricruz Anaya-Ruiz

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 13

Top Topics

Low Density Lipoprotein

Immune Response

Top Venues

Expert opinion on therapeutic patents

Pharmaceutical patent analyst

Expert opinion on drug discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Nemesio Villa-Ruano, Maricruz Anaya-Ruiz, Luis Villafaña-Diaz, Diana Barron-Villaverde, Perez-Santos Martin
Drug repurposing of Mito-Atovaquone for cancer treatment. Pharmaceutical patent analyst (2023)
Maricruz Anaya-Ruiz, Perez-Santos Martin
Drug repurposing of adapalene for melanoma treatment. Pharmaceutical patent analyst 11 (1) (2022)
Perez-Santos Martin, Maricruz Anaya-Ruiz, Luis Villafaña-Diaz, Gabriela Sánchez Esgua
Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents. Expert opinion on drug discovery (2022)
Perez-Santos Martin, Maricruz Anaya-Ruiz, Gabriela Sánchez Esgua, Luis Villafaña-Diaz, Diana Barron-Villaverde
Treatment of solid tumors using bispecific anti-PDL-1/ICOS antibody. Pharmaceutical patent analyst 10 (2) (2021)
Maricruz Anaya-Ruiz, Perez-Santos Martin
Small-molecule inhibitor PD-1/PD-L1 interaction for colorectal cancer treatment. Pharmaceutical patent analyst (2021)
Lourdes Millán-Pérez Peña, Perez-Santos Martin, Irma Herrera-Camacho, Bandala Cindy, Maricruz Anaya-Ruiz
Colon carcinoma treatment using bispecific anti-GITR/CTLA-4 antibodies: a patent evaluation of WO2018091739. Expert opinion on therapeutic patents 30 (5) (2020)
Jorge Cebada, Perez-Santos Martin, Bandala Cindy, Eleazar Lara-Padilla, Irma Herrera-Camacho, Nora Hilda Rosas-Murrieta, Lourdes Millán-Perez Peña, Eduardo Monjaraz, Amira Flores, Maricruz Anaya-Ruiz
OX40 agonists for cancer treatment: a patent review. Expert opinion on therapeutic patents 31 (1) (2020)
Perez-Santos Martin, Maricruz Anaya-Ruiz, Irma Herrera-Camacho, Nora Hilda Rosas-Murrieta, Lourdes Millán-Pérez Peña
Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536. Expert opinion on therapeutic patents 30 (2) (2020)
Perez-Santos Martin, Maricruz Anaya-Ruiz, Irma Herrera-Camacho, Lourdes Millán-Pérez Peña, Nora Hilda Rosas-Murrieta
Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649. Expert opinion on therapeutic patents 29 (12) (2019)
Perez-Santos Martin, Maricruz Anaya-Ruiz, Jorge Cebada, Bandala Cindy, Gerardo Landeta, Patricia Martínez-Morales, Nemesio Villa-Ruano
LAG-3 antagonists by cancer treatment: a patent review. Expert opinion on therapeutic patents 29 (8) (2019)
Perez-Santos Martin, Maricruz Anaya-Ruiz, Irma Herrera-Camacho, Lourdes Millán-Pérez Peña
Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1. Expert opinion on therapeutic patents 29 (7) (2019)
Irma Herrera-Camacho, Maricruz Anaya-Ruiz, Perez-Santos Martin, Lourdes Millán-Pérez Peña, Bandala Cindy, Gerardo Landeta
Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1. Expert opinion on therapeutic patents 29 (8) (2019)
Perez-Santos Martin, Maricruz Anaya-Ruiz, Jorge Cebada, Irma Herrera-Camacho
Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1. Expert opinion on therapeutic patents 29 (5) (2019)